Precision therapy to target apoptosis in prostate cancer

Androgen-independent prostate cancer shows limited response to existing systemic therapies. Recent advances in prostate-selective targeting of small molecule inhibitors and bacterial toxins have created opportunities to design a new generation of therapies for advanced prostate cancer. Yet prioritiz...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Experimental Oncology
Datum:2014
1. Verfasser: Kulik, G.
Format: Artikel
Sprache:English
Veröffentlicht: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2014
Schlagworte:
Online Zugang:https://nasplib.isofts.kiev.ua/handle/123456789/145372
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Zitieren:Precision therapy to target apoptosis in prostate cancer / G. Kulik // Experimental Oncology. — 2014. — Т. 36, № 4. — С. 226-230. — Бібліогр.: 48 назв. — англ.

Institution

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id nasplib_isofts_kiev_ua-123456789-145372
record_format dspace
spelling Kulik, G.
2019-01-21T08:29:32Z
2019-01-21T08:29:32Z
2014
Precision therapy to target apoptosis in prostate cancer / G. Kulik // Experimental Oncology. — 2014. — Т. 36, № 4. — С. 226-230. — Бібліогр.: 48 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/145372
Androgen-independent prostate cancer shows limited response to existing systemic therapies. Recent advances in prostate-selective targeting of small molecule inhibitors and bacterial toxins have created opportunities to design a new generation of therapies for advanced prostate cancer. Yet prioritizing targets for these therapies remain challenging, since multiple mechanisms contribute to the pathophysiology of androgen-independent prostate cancer. This review explores the possibility of targeting the apoptosis regulatory network as most direct approach to efficient treatment of advanced androgen-independent prostate cancer. Key Words: prostate cancer, apoptosis, prostate-selective therapies, PSA-activated pro-drugs, PSMA-targeting toxins.
This work was supported by Internal Research Grant (IRG2014 Project number 4071101011411) from Alfaisal University. The author is grateful to Karen Klein (Biomedical Research Services and Administration, Wake Forest University Health Sciences) for manuscript editing.
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Reviews
Precision therapy to target apoptosis in prostate cancer
Article
published earlier
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
title Precision therapy to target apoptosis in prostate cancer
spellingShingle Precision therapy to target apoptosis in prostate cancer
Kulik, G.
Reviews
title_short Precision therapy to target apoptosis in prostate cancer
title_full Precision therapy to target apoptosis in prostate cancer
title_fullStr Precision therapy to target apoptosis in prostate cancer
title_full_unstemmed Precision therapy to target apoptosis in prostate cancer
title_sort precision therapy to target apoptosis in prostate cancer
author Kulik, G.
author_facet Kulik, G.
topic Reviews
topic_facet Reviews
publishDate 2014
language English
container_title Experimental Oncology
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
format Article
description Androgen-independent prostate cancer shows limited response to existing systemic therapies. Recent advances in prostate-selective targeting of small molecule inhibitors and bacterial toxins have created opportunities to design a new generation of therapies for advanced prostate cancer. Yet prioritizing targets for these therapies remain challenging, since multiple mechanisms contribute to the pathophysiology of androgen-independent prostate cancer. This review explores the possibility of targeting the apoptosis regulatory network as most direct approach to efficient treatment of advanced androgen-independent prostate cancer. Key Words: prostate cancer, apoptosis, prostate-selective therapies, PSA-activated pro-drugs, PSMA-targeting toxins.
issn 1812-9269
url https://nasplib.isofts.kiev.ua/handle/123456789/145372
citation_txt Precision therapy to target apoptosis in prostate cancer / G. Kulik // Experimental Oncology. — 2014. — Т. 36, № 4. — С. 226-230. — Бібліогр.: 48 назв. — англ.
work_keys_str_mv AT kulikg precisiontherapytotargetapoptosisinprostatecancer
first_indexed 2025-12-07T16:13:04Z
last_indexed 2025-12-07T16:13:04Z
_version_ 1850866646699212800